Multimodal treatment of HCC, Bile duct cancer and metastatic liver cancer: a multi-institutional retrospective study

Multimodal treatment of HCC, Bile duct cancer and metastatic liver cancer: a multi-institutional retrospective study - Multimodal treatment of HCC, Bile duct cancer and metastatic liver cancer: a multi-institutional retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033823

Enrollment

3500

Registered

2018-10-01

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma, intrahepatic cholangiocarcinoma, neuroendocrine or colorectal liver metastases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Surgical resection for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, colorectal liver metastases, or neuroendocrine liver metastases

Exclusion criteria

Exclusion criteria: No pathologic confirmation of tumor Age <18 years

Design outcomes

Primary

Measure	Time frame
long-term outcomes of patients from multimodal treatment	—

Countries

Japan,Asia(except Japan),North America,Australia,Europe

Contacts

Public ContactKota Sahara

Yokohama City University Hospital Gastoenterological Surgery

s.kota90@gmail.com045-787-2800

Outcome results